BUY MBP DACLATASVIR AND SOFOSBUVIR HEPCINAT PLUS 28TAB BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Daclatasvir and sofosbuvir are antiviral medicines used together to treat chronic hepatitis C virus infection. This combination is one of the most effective and well-tolerated treatments available for hepatitis C and is used across many virus genotypes. When taken correctly, daclatasvir and sofosbuvir can completely cure hepatitis C in the majority of patients by eliminating the virus from the body.

Daclatasvir works by blocking a protein called NS5A, which the hepatitis C virus needs in order to replicate and assemble new viral particles. Sofosbuvir works by inhibiting another viral enzyme called NS5B RNA polymerase, which is essential for viral replication. By targeting two different steps in the virus life cycle, the combination prevents the virus from multiplying and allows the immune system to clear the infection. This dual mechanism is why the combination is highly effective and has a very high cure rate.

Daclatasvir and sofosbuvir are taken orally, usually once daily, with or without food. They should be taken at the same time every day to maintain stable drug levels in the body. Treatment typically lasts 12 weeks, but in some cases such as advanced liver disease, previous treatment failure, or certain genotypes, treatment may be extended to 24 weeks. It is very important to complete the full course even if symptoms improve early, as stopping treatment early can allow the virus to return.

Once treatment begins, the viral load usually drops rapidly, often becoming undetectable within the first few weeks. Many patients notice improvements in energy, appetite, and general wellbeing during treatment. A cure is confirmed when the virus remains undetectable in the blood 12 weeks after completing therapy, a state known as sustained virologic response. Achieving this means the hepatitis C infection is considered cured.

Daclatasvir and sofosbuvir are generally very well tolerated. The most common side effects are mild and may include fatigue, headache, nausea, mild stomach discomfort, and difficulty sleeping. These effects usually improve as the body adjusts to the medication. When ribavirin is added to the treatment, side effects may be more noticeable and can include anaemia, weakness, shortness of breath, and irritability.

This combination can interact with certain medications. Drugs such as rifampicin, carbamazepine, phenytoin, phenobarbital, and St John?s wort can significantly reduce the effectiveness of treatment and should not be taken at the same time. Some heart medications, antifungal drugs, and HIV treatments may also require dose adjustments or close monitoring. It is important to inform the healthcare provider of all medications, supplements, or herbal products being used.

Before starting treatment, patients are usually screened for hepatitis B, as reactivation of hepatitis B can occur during or after hepatitis C treatment. Liver function tests and viral load tests are also done before and during treatment to monitor progress and safety.

Daclatasvir and sofosbuvir should not be used during pregnancy unless clearly advised by a specialist. If ribavirin is included in the treatment, pregnancy must be strictly avoided due to the risk of serious birth defects. Effective contraception is required during treatment and for a period after completing therapy when ribavirin is used.

These medicines do not protect against reinfection with hepatitis C. Safe practices should continue, especially for individuals at ongoing risk of exposure. Treatment also does not prevent transmission until cure is confirmed, so precautions should remain in place throughout therapy.

When taken correctly under medical supervision, daclatasvir and sofosbuvir offer a highly effective, well-tolerated, and life-changing treatment for hepatitis C. They significantly reduce the risk of liver damage, cirrhosis, liver failure, and liver cancer, allowing many people to regain long-term liver health and quality of life.